Precision engineering of targeted nanocarriers

Abstract

Since their introduction in 1980, the number of advanced targeted nanocarrier systems has grown considerably. Nanocarriers capable of targeting single receptors, multiple receptors, or multiple epitopes have all been used to enhance delivery efficiency and selectivity. Despite tremendous progress, preclinical studies and clinically translatable nanotechnology remain disconnected. The disconnect in targeting efficacy may stem from poorly-understood factors such as receptor clustering, spatial control of targeting ligands, ligand mobility, and ligand architecture. Further, the relationship between receptor distribution and ligand architecture remains elusive. Traditionally, targeted nanocarriers were engineered assuming a "static" target. However, it is becoming increasingly clear that receptor expression patterns change in response to external stimuli and disease progression. Here, we discuss how cutting-edge technologies will enable a better characterization of the spatiotemporal distribution of membrane receptors and their clustering. We further describe how this will enable the design of new nanocarriers that selectively target the site of disease. Ultimately, we explore how the precision engineering of targeted nanocarriers that adapt to receptor dynamics will have the potential to drive nanotechnology to the forefront of therapy and make targeted nanomedicine a clinical reality. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Biology-Inspired Nanomaterials > Lipid-Based Structures Biology-Inspired Nanomaterials > Protein and Virus-Based Structures.

Mechanisms of NF-κB p65 and strategies for therapeutic manipulation

“…In future, development of engineered nanocarriers will not only facilitate targeted delivery but also accommodate conformational changes needed for efficacious intracellular p65 inhibitors. 1 , 133 …”

Modulating Macrophage Polarization through CCR2 Inhibition and Multivalent Engagement

“…37 Furthermore, there have been no targeted or multivalent nanocarriers approved by the FDA because of poor understanding for nanocarrier-target interactions. 38, 39…”

Integrin-Mediated Delivery of Drugs and Nucleic Acids for Anti-Angiogenic Cancer Therapy: Current Landscape and Remaining Challenges

“…There is room for improvement in design strategies to generate integrin ligands with even higher specificity. Detailed structure–activity relationships with due consideration to zeta potential, hydrodynamic diameter, flexibility of ligand-display, multi-valency and spatial segregation of ligands, shape of the vehicle [55], drug-encapsulation and release-kinetics are needed to be investigated for proper optimization of the vehicle [131,132]. In-depth research is needed to address the effects of integrin internalization, recycling and saturation to control the delivered drug.…”